beta-lactams has been researched along with Critical Illness in 125 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (5.60) | 29.6817 |
| 2010's | 61 (48.80) | 24.3611 |
| 2020's | 57 (45.60) | 2.80 |
| Authors | Studies |
|---|---|
| Burgess, DS; Clark, JA; Landmesser, KB | 1 |
| Besch, G; Capellier, G; Chaignat, C; Clairet, AL; Despres, C; Floury, SP; Labro, G; Lagoutte-Renosi, J; Montange, D; Piton, G; Puyraveau, M; Vettoretti, L; Vivet, B; Winiszewski, H | 1 |
| Bitker, L; Boidin, C; Friggeri, A; Goutelle, S; Matusik, E; Richard, JC; Roberts, JA | 1 |
| Abdulla, A; de Winter, BCM; Endeman, H; Ewoldt, TMJ; Hunfeld, NGM; Koch, BCP; Muller, AE | 1 |
| Abdulla, A; Endeman, H; Ewoldt, TMJ; Koch, BCP; Muller, AE; van den Broek, P | 1 |
| Brinkmann, A; Chiriac, U; Frey, OR; Fuchs, T; Heininger, A; Rau, H; Richter, DC; Röhr, AC; Weigand, MA | 1 |
| Chua, NG; Cove, M; Hee, DKH; Hoo, GSR; Kwa, AL; Lee, LS; Lee, W; Lim, TP; Ling, LM; Loo, L; Ng, TM; Ong, JCL; Soong, JL; Tang, SSL; Zhou, YP | 1 |
| Barreto, EF; Fugate, JE; Gajic, O; Haddad, NA; Hocker, SE; Ice, CJ; Leung, SB; Mara, KC; Rabinstein, AA; Rule, AD; Schreier, DJ | 1 |
| Lizza, BD; Micek, ST; Raush, N | 1 |
| Gorham, J; Hites, M; Taccone, FS | 1 |
| De Cock, PAJG; De Paepe, P; Delanghe, JR; Dhont, E; Herck, I; Stove, V; Van Der Heggen, T; Vanhaesebrouck, S; Verstraete, AG; Willems, J | 1 |
| Alshaer, MH; Bai, C; Felton, TW; Maguigan, KL; Maranchick, N; Mardini, MT; Mathew, SK; Peloquin, CA; Shoulders, B | 1 |
| Alshaer, MH; Cherabuddi, K; DeSear, K; Hamza, M; Peloquin, CA; Santevecchi, B; Venugopalan, V | 1 |
| Ashok, A; Lee, SJ; Pai Mangalore, R; Peel, TN; Peleg, AY; Romero, L; Udy, AA | 1 |
| Autmizguine, J; Marsot, A; Thibault, C | 1 |
| Alshaer, M; Burch, G; Carson, J; Drabick, Z; Mazirka, P; Peloquin, C | 1 |
| Abdul-Aziz, MH; Roberts, JA; Sulaiman, H | 1 |
| Abdulla, A; de Winter, BCM; Draisma, A; Endeman, H; Ewoldt, TMJ; Gommers, D; Haringman, J; Hunfeld, NGM; Karakus, A; Koch, BCP; Muller, AE; Purmer, IM; Rietdijk, WJR; Rijpstra, TA; van Vliet, P; Wils, EJ | 1 |
| Béranger, A; Bille, E; Callot, D; Chouchana, L; Debray, A; Hirt, D; Oualha, M; Renolleau, S; Tréluyer, JM | 1 |
| Eliasson, E; Furebring, M; Lipcsey, M; Smekal, AK | 1 |
| Alexander, KM; Alshaer, MH; Felton, TW; Manigaba, K; Maranchick, N; Mathew, SK; Peloquin, CA; Shoulders, BR | 1 |
| Nicholls, S; Robson, C; Rogers, BA; Sandaradura, I; Stuart, R; Tan, B | 1 |
| Dalton, B; Zeggil, T | 1 |
| Dräger, S; Endeman, H; Koch, BCP; Rietdijk, WJR | 1 |
| Abdul Aziz, MH; Alshaer, MH; Ausman, SE; Barreto, EF; Boehmer, KR; Chitre, PN; Jannetto, PJ; Mara, KC; Moreland-Head, LN; Pine, KH; Rivera, CG; Roberts, JA; Rule, AD; Scheetz, MH; Shepel, KK | 1 |
| Klompas, M; Rhee, C; Shappell, CN | 1 |
| Pai Mangalore, R; Peel, TN; Peleg, AY; Udy, AA | 1 |
| Batteux, B; Bennis, Y; Bodeau, S; Gaulin, C; Kontar, L; Lemaire-Hurtel, AS; Maizel, J; Zerbib, Y | 1 |
| Greco Kinney, A; Hadique, S; Jain, P; Kovacic Scherrer, N; Sarkar, S; Wen, S | 1 |
| Furebring, M; Giske, CG; Lipcsey, M; Smekal, AK | 1 |
| Csomós, Á; Erőss, A; Farkas, R; Galgóczi, J; Holub, L; Karvaly, G; Lakatos, B; Rádler, A; Szabó, BG; Tóth, B; Závorszky, L | 1 |
| Jang, SM; Mueller, BA; Pai, MP; Shaw, AR | 1 |
| Boidin, C; Dahyot-Fizelier, C; Goutelle, S; Lefeuvre, S; Moshiri, P | 1 |
| Cotta, MO; Roberts, JA; Williams, P | 1 |
| Birckener, J; Butin-Druoton, AL; Germain, A; Guerci, P; Leon, L; Losser, MR; Luc, A; Novy, E; Pape, E; Scala-Bertola, J; Thilly, N | 1 |
| Briscoe, S; Lipman, J; McWhinney, B; Nunez-Nunez, M; Rhodes, NJ; Roberts, JA; Scheetz, MH; Taccone, F; Ungerer, J; Villois, P; Wong, G | 1 |
| Biais, M; Carrié, C; Chadefaux, G; de Courson, H; Nouette-Gaulain, K; Pereira, B; Petit, L; Sauvage, N | 1 |
| Crass, RL; Roberts, JA; Williams, P | 1 |
| Abdulla, A; Endeman, H; Ewoldt, TMJ; Hunfeld, NGM; Koch, BCP; Muller, AE; Polinder, S; Rietdijk, WJR; van Gelder, T | 1 |
| Hampton, NB; Kollef, MH; Micek, ST; Teshome, BF; Vouri, SM | 1 |
| Guerci, P; Novy, E; Roger, C; Scala-Bertola, J | 1 |
| Abdul-Aziz, MH; Alffenaar, JC; Bassetti, M; Bracht, H; De Waele, JJ; Dimopoulos, G; Marriott, D; Neely, MN; Paiva, JA; Pea, F; Roberts, JA; Sjovall, F; Timsit, JF; Udy, AA; Wicha, SG; Zeitlinger, M | 1 |
| Albasanz-Puig, A; Arnan, M; Batlle, M; Carmona-Torre, F; Carratalà, J; Del Pozo, JL; Garcia-Vidal, C; Gudiol, C; Huguet, M; Laporte-Amargos, J; Muñoz, C; Padullés, A; Parody, R; Puerta-Alcalde, P; Rigo-Bonnin, R; Sureda, A; Tebé, C; Tubau, F; Videla, S | 1 |
| Černý, D; Halačová, M; Sadilová, K | 1 |
| Aboulatta, L; Noma, H; Sasaki, T; Sugita, H; Wakabayashi, H | 1 |
| Cusumano, JA; Huttner, A; Klinker, KP; LaPlante, KL; Luther, MK; Roberts, JA | 1 |
| Boelens, J; De Waele, J; Dhaese, S; Van Vooren, S | 1 |
| Al-Shaer, MH; Cherabuddi, K; Klinker, K; Peloquin, C; Rubido, E; Venugopalan, V | 1 |
| Baker, EH; Barker, CIS; Johnston, A; Kipper, K; Lonsdale, DO; Oldfield, I; Philips, BJ; Rhodes, A; Sharland, M; Standing, JF | 1 |
| Andersen, CØ; Bathum, L; Benfield, T; Frimodt-Møller, N; Munk, JK; Tanha, N | 1 |
| Abdul-Aziz, MH; Portunato, F; Roberts, JA | 1 |
| Benken, LA; Chamberlain, AR; Jones, RL; Kaplan, JM; Murphy, ME; Stoneman, EM; Tang Girdwood, SC; Tang, PH; Vinks, AA | 1 |
| Su, YC; Wu, CC; Wu, KS; Wu, TH; Yang, CS | 1 |
| Lambiotte, F; Lemtir, J; Matusik, E; Tone, A | 1 |
| Abdulla, A; Endeman, H; Ewoldt, TMJ; Gommers, D; Koch, BCP; Muller, AE; Purmer, IM | 1 |
| Alffenaar, JW; Friberg, LE; Koch, BCP; Märtson, AG; Minichmayr, IK; Nielsen, EI; Wicha, SG | 1 |
| Gatti, M; Pea, F | 1 |
| Abdulla, A; Endeman, H; Ewoldt, TMJ; Gommers, D; Hunfeld, NGM; Koch, BCP; Muller, AE; Polinder, S | 1 |
| Brinkmann, A; Chiriac, U; Frey, OR; Fuchs, T; Gronau, P; Koeberer, A; Roberts, JA; Roehr, AC | 1 |
| Economou, CJP; Lipman, J; McWhinney, B; Roberts, JA; Ungerer, JPJ; Wong, G | 1 |
| Bassetti, M; Brüggemann, RJ; Bulitta, JB; De Waele, JJ; Felton, TW; Friberg, LE; Marchand, S; Nielsen, EI; Ramos Martín, V; Roberts, JA; Tam, VH; Tängdén, T; Theuretzbacher, U; Tsuji, BT; Wareham, DW | 1 |
| Aubron, C; Corallo, C | 1 |
| Delattre, IK; Dugernier, T; Hites, M; Jacobs, F; Laterre, PF; Spapen, H; Taccone, FS; Tulkens, PM; Van Bambeke, F; Wallemacq, PE | 1 |
| Kanafani, ZA; Kanj, SS; Rizk, NA; Tabaja, HZ | 1 |
| Bos, JC; Prins, JM; van Hest, RM | 1 |
| Baptista, JP; Froes, F; Gonçalves-Pereira, J; Paiva, JA; Pereira, JM; Ribeiro, O | 1 |
| Bonten, MJM; Cremer, OL; Ong, DSY; Thwaites, GE; van Werkhoven, CH | 1 |
| Alzghari, SK; Blanco, DD; Hager, JD; Kuntz, KS; Lee, YR; Miller, PD | 1 |
| Abdul-Aziz, MH; Lipman, J; Roberts, JA | 1 |
| Heffernan, A; Lipman, J; Roberts, J | 1 |
| Roberts, JA | 1 |
| Ally, M; Briscoe, S; Lipman, J; McWhinney, B; Roberts, JA; Ungerer, J; Wong, G | 1 |
| Bartoletti, M; Giannella, M; Lewis, RE; Tedeschi, S; Viale, P | 1 |
| Paiva, JA; Veiga, RP | 1 |
| Hampton, N; Kollef, MH; Micek, ST; Teshome, BF; Vouri, SM | 1 |
| Billot, L; Brett, SJ; Cotta, MO; Davis, JS; De Waele, JJ; Dulhunty, JM; Finfer, S; Glass, P; Knowles, S; Lipman, J; McGuinness, S; Myburgh, J; Paterson, DL; Peake, S; Rajbhandari, D; Rhodes, A; Roberts, JA; Shirwadkar, C; Starr, T; Taylor, C | 1 |
| Barreto, EF; Rule, AD; Schreier, DJ | 1 |
| Bellomo, R; Davis, JS; Dulhunty, JM; Eastwood, GM; Gomersall, C; Lipman, J; Myburgh, J; Paterson, DL; Paul, SK; Roberts, JA; Shirwadkar, C; Starr, T; Udy, AA; Webb, SA | 1 |
| Adnan, S; Briscoe, S; Lipman, J; McWhinney, B; Roberts, JA; Ungerer, J; Wong, G | 1 |
| Adrie, C; Azoulay, E; Darmon, M; Dinh-Xuan, AT; Garrouste-Orgeas, M; Jamali, S; Kallel, H; Planquette, B; Schwebel, C; Souweine, B; Timsit, JF; Vignoud, L; Zahar, JR | 1 |
| DePestel, DD; Eyler, RF; Heung, M; Kinzig, M; Mueller, BA; Nader, AM; Pleva, M; Sörgel, F; Sowinski, KM; Vilay, AM | 1 |
| Akova, M; Bassetti, M; De Waele, JJ; Dimopoulos, G; Kaukonen, KM; Koulenti, D; Lipman, J; Martin, C; Montravers, P; Paul, SK; Rello, J; Rhodes, A; Roberts, JA; Starr, T; Wallis, SC | 2 |
| Craig, WA | 1 |
| Blot, S; Cotta, MO; Lipman, J; Roberts, JA; Tabah, A; Vogelaers, D | 1 |
| Kuti, JL; MacVane, SH; Rhodes, NJ; Scheetz, MH | 1 |
| Calvo, G; Llauradó-Serra, M; Martín-Loeches, I; Pontes, C; Soy, D; Ulldemolins, M; Vaquer, S | 1 |
| Roberts, DM; Roberts, JA | 1 |
| Akova, M; Bassetti, M; De Waele, JJ; Dimopoulos, G; Kaukonen, M; Koulenti, D; Lipman, J; Martin, C; Montravers, P; Rello, J; Rhodes, A; Roberts, JA; Starr, T; Udy, AA; Wallis, SC | 1 |
| Beumier, M; Casu, GS; Cotton, F; Hites, M; Jacobs, F; Taccone, FS; Vincent, JL; Wolff, F | 1 |
| Bahador, A; Esmaeili, D; Jalalvand, N; Kholdi, S; Nasrolahei, M; Saghi, H; Zahedi, B | 1 |
| Affaticati, M; Daali, Y; Fathi, M; Harbarth, S; Huttner, A; Huttner, BD; Karmime, A; Lew, D; Pagani, L; Pugin, J; Renzoni, A; Von Dach, E | 1 |
| De Waele, JJ; Lipman, J; Udy, AA | 1 |
| Bursle, E; Cotta, MO; Gowen, B; Lipman, J; McWhinney, B; Roberts, JA; Truloff, N; Ungerer, JP | 1 |
| Carlier, M; De Waele, JJ; Lipman, J; Roberts, JA; Stove, V; Verstraete, AG | 1 |
| Roberts, JA; Sime, FB; Udy, AA | 1 |
| Andresen V, M; Andresen, M; Silva, C; Soto, D; Soto, N; Wong, KY | 1 |
| Abd Rahman, AN; Abdul-Aziz, MH; Hasan, MS; Jamal, JA; Lipman, J; Mat-Nor, MB; Rai, V; Roberts, JA; Staatz, CE; Sulaiman, H; Wallis, SC; Wong, KK | 1 |
| Laupland, KB; Montravers, P; Taccone, FS | 1 |
| Agrinier, N; Charmillon, A; Dellamonica, J; Demoré, B; Kimmoun, A; Leone, M; Levy, B; Novy, E; Pulcini, C | 1 |
| Cotta, MO; Dulhunty, JM; Lipman, J; Myburgh, J; Roberts, JA | 1 |
| Al-Hasan, MN; Ereshefsky, BJ; Gokun, Y; Martin, CA | 1 |
| Fridlund, J; Schön, T; Woksepp, H | 1 |
| Abdul-Aziz, MH; Balestra, G; Osthoff, M; Roberts, JA; Siegemund, M | 1 |
| Burkhardt, O; Fliser, D; Hafer, C; Haller, H; Kaever, V; Kielstein, JT; Kumar, V; Langhoff, A; Welte, T | 1 |
| Brink, AJ; Kiem, S; Richards, GA; Schentag, J; Schillack, V | 1 |
| Burkhardt, O; Derendorf, H; Kielstein, JT; Kumar, V; Schmidt, S; Welte, T | 1 |
| Cumps, J; Delattre, IK; Dugernier, T; Jacobs, F; Laterre, PF; Musuamba, FT; Spapen, H; Taccone, FS; Verbeeck, RK; Vincent, JL; Wallemacq, PE; Wittebole, X | 1 |
| Hope, WW; Lipman, J; Roberts, JA | 1 |
| Lipman, J; McWhinney, B; Paterson, DL; Roberts, JA; Roberts, MS; Ulldemolins, M; Ungerer, J | 1 |
| Jeurissen, A; Rutsaert, R | 1 |
| Boselli, E; Breilh, D; Fleureau, C; Gordien, JB; Janvier, G; Joanes-Boyau, O; Rapaport, S; Saux, MC; Texier-Maugein, J | 1 |
| Kirkpatrick, CM; Lipman, J; Mohd Hafiz, AA; Roberts, JA; Staatz, CE | 1 |
| Gonçalves-Pereira, J; Póvoa, P | 1 |
| Altukroni, M; Briscoe, S; Lipman, J; McWhinney, BC; Roberts, JA; Udy, AA; Ungerer, JP; Varghese, JM | 1 |
| Delattre, IK; Jacobs, F; Jacqmin, P; Laterre, PF; Musuamba, FT; Taccone, FS; Verbeeck, RK; Wallemacq, P | 1 |
| Lipman, J; Roberts, JA; Roberts, MS; Sinnollareddy, MG | 1 |
| Shorr, AF | 1 |
| Economou, CJ; Jamal, JA; Lipman, J; Roberts, JA | 1 |
| Hayashi, Y; Lipman, J; Lust, K; McWhinney, B; Ng, M; Roberts, JA; Udy, AA; Ungerer, J | 1 |
| Bodmann, KF | 1 |
| Burkhardt, O; Derendorf, H; Drewelow, B; Katterwe, D; Kumar, V; Majcher-Peszynska, J; Welte, T | 1 |
| Drusano, GL; Lodise, TP; Lomaestro, B | 1 |
| Burkhardt, O; Derendorf, H; Welte, T | 1 |
| Lipman, J; Roberts, JA | 1 |
39 review(s) available for beta-lactams and Critical Illness
| Article | Year |
|---|---|
Therapeutic Drug Monitoring of Antibiotic Drugs in Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis: A Critical Review.
Topics: Anti-Bacterial Agents; beta-Lactams; Continuous Renal Replacement Therapy; Critical Illness; Drug Monitoring; Humans; Renal Dialysis; Renal Replacement Therapy | 2022 |
Therapeutic Drug Monitoring of Antibiotics in Critically Ill Patients: Current Practice and Future Perspectives With a Focus on Clinical Outcome.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Monitoring; Humans; Vancomycin | 2022 |
Barriers and Facilitators in the Clinical Implementation of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: A Critical Review.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Monitoring; Humans | 2022 |
Antibiotic Stewardship and Therapeutic Drug Monitoring of β-Lactam Antibiotics: Is There a Link? An Opinion Paper.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; beta-Lactams; Critical Illness; Drug Monitoring; Humans; Intensive Care Units | 2022 |
Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Monitoring; Glycopeptides; Humans; Intensive Care Units | 2022 |
Beta-Lactam Antibiotic Therapeutic Drug Monitoring in Critically Ill Patients: A Systematic Review and Meta-Analysis.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Monitoring; Humans; Monobactams; Prospective Studies | 2022 |
A systematic review of optimal pharmacokinetic/pharmacodynamic parameters for beta-lactam therapy in infective endocarditis.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Endocarditis, Bacterial; Humans; Monobactams | 2023 |
The clinical application of beta-lactam antibiotic therapeutic drug monitoring in the critical care setting.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Care; Critical Illness; Drug Monitoring; Humans; Monobactams | 2023 |
Pharmacokinetic variability of beta-lactams in critically ill patients: A narrative review.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Care; Critical Illness; Drug Monitoring; Humans; Pharmacokinetics | 2020 |
Pharmacokinetics/Pharmacodynamics of β-Lactams and Therapeutic Drug Monitoring: From Theory to Practical Issues in the Intensive Care Unit.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Monitoring; Humans; Infusions, Intravenous; Intensive Care Units; Practice Guidelines as Topic; Software | 2019 |
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Critical Illness; Drug Monitoring; Humans | 2020 |
Comparison of extended versus intermittent infusion of antipseudomonal beta-lactams for the treatment of critically ill patients with respiratory infections: A systematic review and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Data Management; Humans; Infusion Pumps; Length of Stay; Middle Aged; Pseudomonas; Respiratory Tract Infections; Time Factors; Treatment Outcome | 2020 |
Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity.
Topics: Aged; Anti-Bacterial Agents; Area Under Curve; beta-Lactams; Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Bacterial; Humans; Obesity; Precision Medicine; Vancomycin | 2020 |
Therapeutic drug monitoring of β-lactam antibiotics in the ICU.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; beta-Lactams; Critical Care; Critical Illness; Drug Monitoring; Humans; Intensive Care Units; Precision Medicine | 2020 |
[Therapeutic drug monitoring of β-lactam antibiotics].
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Monitoring; Humans; Obesity | 2020 |
Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Cystic Fibrosis; Drug Monitoring; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Immunocompromised Host; Infusions, Intravenous; Microbial Sensitivity Tests; Middle Aged; Respiratory Tract Infections; Severity of Illness Index | 2020 |
Loading dose and efficacy of continuous or extended infusion of beta-lactams compared with intermittent administration in patients with critical illnesses: A subgroup meta-analysis and meta-regression analysis.
Topics: APACHE; beta-Lactams; Critical Illness; Drug Administration Schedule; Hospital Mortality; Humans; Infusions, Intravenous; Length of Stay; Microbial Sensitivity Tests; Randomized Controlled Trials as Topic; Respiration, Artificial | 2021 |
[Pharmacokinetic modifications and pharmacokinetic/pharmacodynamic optimization of beta-lactams in ICU].
Topics: Anti-Bacterial Agents; Bayes Theorem; beta-Lactams; Critical Illness; Humans; Intensive Care Units; Microbial Sensitivity Tests | 2021 |
A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients.
Topics: Age Factors; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Precision Medicine; Sex Factors | 2021 |
From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics.
Topics: Algorithms; Aminoglycosides; Anti-Bacterial Agents; Area Under Curve; beta-Lactams; Biomarkers; Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Glycopeptides; Half-Life; Humans; Linezolid; Microbial Sensitivity Tests; Models, Biological; Precision Medicine | 2021 |
Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors.
Topics: Bacterial Infections; beta-Lactamase Inhibitors; beta-Lactams; Critical Illness; Dose-Response Relationship, Drug; Drug Development; Drug Monitoring; Drug Resistance, Multiple, Bacterial; Humans; Kidney Diseases | 2021 |
The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; beta-Lactams; Biomarkers; Critical Illness; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Monitoring; Glycopeptides; Humans; Intensive Care Units; Quinolones; Severity of Illness Index | 2017 |
Extended infusion of beta-lactam antibiotics: optimizing therapy in critically-ill patients in the era of antimicrobial resistance.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Critical Illness; Drug Administration Schedule; Drug Resistance, Bacterial; Humans | 2017 |
Pharmacokinetics of Antibiotics in Sub-Saharan African Patient Populations: A Systematic Review.
Topics: Africa South of the Sahara; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Observational Studies as Topic; Population Surveillance | 2017 |
Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Respiratory Tract Infections; Retrospective Studies | 2018 |
The role of extended infusion β-lactams in the treatment of bloodstream infections in patients with liver cirrhosis.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactams; Critical Illness; Drug Resistance, Multiple, Bacterial; Humans; Infusions, Intravenous; Liver Cirrhosis; Microbial Sensitivity Tests; Randomized Controlled Trials as Topic; Time Factors | 2018 |
Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Monitoring; Drug Utilization Review; Humans; Infusions, Intravenous | 2018 |
Antimicrobial stewardship of β-lactams in intensive care units.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Critical Illness; Drug Dosage Calculations; Enterobacteriaceae; Enterobacteriaceae Infections; Guidelines as Topic; Humans; Intensive Care Units; Microbial Sensitivity Tests; Precision Medicine | 2014 |
Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.
Topics: Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Critical Illness; Humans; Meropenem; Piperacillin; Renal Replacement Therapy; Shock, Septic; Thienamycins | 2014 |
Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Dose-Response Relationship, Drug; Humans; Kidney | 2015 |
[Therapeutic monitoring of antibiotics: New methodologies: biosensors].
Topics: Anti-Bacterial Agents; beta-Lactams; Biosensing Techniques; Critical Illness; Drug Monitoring; Fluorescence; Humans | 2015 |
Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Infusions, Intravenous; Intensive Care Units; Microbial Sensitivity Tests; Outcome Assessment, Health Care | 2016 |
Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Child; Critical Care; Critical Illness; Cystic Fibrosis; Fever; Humans; Infusions, Intravenous; Length of Stay; Leukocyte Count; Neoplasms; Respiration, Artificial; Treatment Outcome | 2012 |
Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Cefpirome; Ceftazidime; Cephalosporins; Critical Illness; Humans; Imipenem; Infections; Meropenem; Piperacillin; Thienamycins | 2011 |
β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.
Topics: beta-Lactam Resistance; beta-Lactams; Critical Illness; Dose-Response Relationship, Drug; Humans; Infusions, Intravenous; Sepsis | 2012 |
Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Burns; Critical Illness; Drug Resistance, Multiple, Bacterial; Extracorporeal Membrane Oxygenation; Glycoproteins; Humans; Intensive Care Units; Renal Replacement Therapy | 2012 |
Current guidelines for the treatment of severe pneumonia and sepsis.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Critical Illness; Cross Infection; Drug Resistance; Germany; Humans; Intensive Care Units; International Cooperation; Pneumonia; Practice Guidelines as Topic; Sepsis; Severity of Illness Index | 2005 |
Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Clinical Trials as Topic; Community-Acquired Infections; Critical Illness; Drug Interactions; Drug Resistance, Bacterial; Endometritis; Ertapenem; Female; Humans; Peritonitis; Protein Binding; Renal Insufficiency; Surgical Wound Infection; Urinary Tract Infections | 2007 |
Optimizing use of beta-lactam antibiotics in the critically ill.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Critical Illness; Humans; Infusion Pumps; Microbial Sensitivity Tests; Treatment Outcome | 2007 |
9 trial(s) available for beta-lactams and Critical Illness
| Article | Year |
|---|---|
Suboptimal Beta-Lactam Therapy in Critically Ill Children: Risk Factors and Outcome.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactams; Child; Critical Illness; Humans; Infant; Meropenem; Piperacillin, Tazobactam Drug Combination; Risk Factors | 2022 |
Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial.
Topics: Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Critical Illness; Humans; Intensive Care Units; Middle Aged; Monobactams | 2022 |
The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial.
Topics: Adult; Anti-Bacterial Agents; Bayes Theorem; beta-Lactams; Critical Illness; Drug Monitoring; Fluoroquinolones; Humans; Intensive Care Units; Length of Stay; Quality of Life | 2020 |
Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Clinical Trials, Phase IV as Topic; Critical Care; Critical Illness; Febrile Neutropenia; Female; Hematologic Neoplasms; Humans; Infusions, Parenteral; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Spain; Treatment Outcome; Young Adult | 2020 |
A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III.
Topics: Anti-Bacterial Agents; Australia; beta-Lactams; Critical Illness; Drug Administration Schedule; Humans; Infusions, Intravenous; Meropenem; New Zealand; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Sepsis; Treatment Outcome; United Kingdom | 2019 |
A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study.
Topics: Adult; Aged; beta-Lactams; Critical Care; Critical Illness; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Sepsis; Treatment Outcome | 2013 |
Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Ertapenem; Female; Gram-Negative Bacterial Infections; Hemofiltration; Humans; Male; Middle Aged; Renal Dialysis | 2014 |
Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Chi-Square Distribution; Critical Care; Critical Illness; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Sepsis; Statistics, Nonparametric | 2016 |
Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Amikacin; Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Critical Illness; Drug Monitoring; Female; Humans; Male; Meropenem; Metabolic Clearance Rate; Middle Aged; Models, Biological; Piperacillin; Sepsis; Thienamycins; Tissue Distribution; Treatment Outcome | 2012 |
77 other study(ies) available for beta-lactams and Critical Illness
| Article | Year |
|---|---|
Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Critical Illness; Humans; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2022 |
β-lactam dosing at the early phase of sepsis: Performance of a pragmatic protocol for target concentration achievement in a prospective cohort study.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Meropenem; Piperacillin; Prospective Studies; Sepsis | 2022 |
Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1).
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Monitoring; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Singapore | 2022 |
Incidence and Predictive Factors Associated with Beta-Lactam Neurotoxicity in the Critically Ill: A Retrospective Cohort Study.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Cohort Studies; Critical Illness; Humans; Incidence; Piperacillin; Retrospective Studies | 2022 |
Antibiotic Optimization in the Intensive Care Unit.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Intensive Care Units; Retrospective Studies; Sepsis; Vancomycin | 2022 |
Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated Pneumonia.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Healthcare-Associated Pneumonia; Hospitals; Humans; Intensive Care Units; Machine Learning; Middle Aged; Pneumonia, Ventilator-Associated | 2022 |
Implementation of a β-lactam therapeutic drug monitoring program: Experience from a large academic medical center.
Topics: Academic Medical Centers; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Monitoring; Humans; Lactams | 2022 |
Beta-Lactams in Critically Ill Children: Time to Step Up Our Game?
Topics: Anti-Bacterial Agents; beta-Lactams; Child; Critical Illness; Humans; Infusions, Intravenous | 2022 |
Experience with Implementing a Beta-lactam Therapeutic Drug Monitoring Service in a Burn Intensive Care Unit: A Retrospective Chart Review.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Burns; Critical Illness; Drug Monitoring; Humans; Intensive Care Units; Retrospective Studies | 2023 |
Pharmacokinetics and pharmacodynamics of beta-lactam antibiotics in critically ill patients.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Intensive Care Units; Monobactams | 2022 |
Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study.
Topics: Anti-Bacterial Agents; Bayes Theorem; beta-Lactams; Cefotaxime; Child; Critical Illness; Humans; Infusions, Intravenous; Meropenem; Piperacillin; Prospective Studies | 2023 |
Low attainment to PK/PD-targets for β-lactams in a multi-center study on the first 72 h of treatment in ICU patients.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cefotaxime; Critical Illness; Humans; Intensive Care Units; Microbial Sensitivity Tests; Monobactams; Prospective Studies | 2022 |
Beta-lactam target attainment and associated outcomes in patients with bloodstream infections.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin, Tazobactam Drug Combination; Sepsis | 2023 |
β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Monitoring; Humans; Sepsis | 2023 |
Beta-lactam Therapeutic Drug Monitoring in Critically ill Patients: Learnings for Future Research.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Monitoring; Humans; Infusions, Intravenous | 2023 |
Why is the Implementation of Beta-Lactam Therapeutic Drug Monitoring for the Critically Ill Falling Short? A Multicenter Mixed-Methods Study.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Monitoring; Humans; Vancomycin | 2023 |
Do Prolonged Infusions of β-Lactam Antibiotics Improve Outcomes in Critically Ill Patients With Sepsis?
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Infusions, Intravenous; Monobactams; Sepsis; Time Factors; Treatment Outcome | 2023 |
Neurological burden and outcomes of excessive β-lactam serum concentrations of critically ill septic patients: a prospective cohort study.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Male; Prospective Studies; Shock, Septic | 2023 |
β-Lactams plus doxycycline versus azithromycin for treatment of severe community-acquired pneumonia in critically ill patients.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Community-Acquired Infections; Critical Illness; Doxycycline; Drug Therapy, Combination; Humans; Pneumonia; Prospective Studies; Treatment Outcome | 2023 |
Swedish multicentre study of target attainments with β-lactams in the ICU: which MIC parameter should be used?
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Intensive Care Units; Microbial Sensitivity Tests; Sweden | 2023 |
[Therapeutic drug monitoring of beta-lactam antibiotics in critically ill adult patients].
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Monitoring; Humans; Monobactams; Sepsis | 2023 |
Antibiotic Exposure Profiles in Trials Comparing Intensity of Continuous Renal Replacement Therapy.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Clinical Trials as Topic; Computer Simulation; Continuous Renal Replacement Therapy; Critical Illness; Dose-Response Relationship, Drug; Humans; Models, Biological; Monte Carlo Method | 2019 |
Serum and peritoneal exudate concentrations after high doses of β-lactams in critically ill patients with severe intra-abdominal infections: an observational prospective study.
Topics: Aged; Ascitic Fluid; beta-Lactams; Critical Illness; Cross Infection; Dose-Response Relationship, Drug; Female; France; Humans; Intraabdominal Infections; Male; Middle Aged; Peritonitis; Prospective Studies | 2020 |
β-Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Sepsis | 2020 |
Increased β-Lactams dosing regimens improve clinical outcome in critically ill patients with augmented renal clearance treated for a first episode of hospital or ventilator-acquired pneumonia: a before and after study.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Dose-Response Relationship, Drug; Female; Healthcare-Associated Pneumonia; Humans; Male; Middle Aged; Pneumonia; Pneumonia, Ventilator-Associated; Retrospective Studies; Treatment Outcome | 2019 |
The challenge of quantifying and managing pharmacokinetic variability of beta-lactams in the critically ill.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Sepsis | 2020 |
Evaluation of a ceiling effect on the association of new resistance development to antipseudomonal beta-lactam exposure in the critically ill.
Topics: Academic Medical Centers; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Cohort Studies; Critical Illness; Drug Resistance, Bacterial; Female; Humans; Male; Middle Aged; Missouri; Pseudomonas; Pseudomonas Infections | 2020 |
Preliminary therapeutic drug monitoring data of β-lactams in critically ill patients with SARS-CoV-2 infection.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; beta-Lactams; Betacoronavirus; Cefepime; Coinfection; Confusion; Coronavirus Infections; COVID-19; Critical Illness; Cross Infection; Deep Sedation; Delirium; Drug Monitoring; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Pandemics; Pneumonia, Ventilator-Associated; Pneumonia, Viral; Respiration, Artificial; SARS-CoV-2; Sepsis | 2020 |
Pharmacokinetic aspects of beta-lactam antibiotic therapy in intensive care unit patients: A one-center experience with TDM.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Critical Illness; Czech Republic; Drug Monitoring; Humans; Intensive Care Units | 2020 |
Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Microbial Sensitivity Tests; Retrospective Studies | 2020 |
β-Lactam antimicrobial pharmacokinetics and target attainment in critically ill patients aged 1 day to 90 years: the ABDose study.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Child; Critical Illness; Humans; Infant, Newborn; Microbial Sensitivity Tests; Prospective Studies | 2020 |
Demonstrating Feasibility of an Opportunistic Sampling Approach for Pharmacokinetic Studies of β-Lactam Antibiotics in Critically Ill Children.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactams; Cefepime; Child; Child, Preschool; Comorbidity; Critical Illness; Feasibility Studies; Female; Humans; Intensive Care Units, Pediatric; Male; Meropenem; Piperacillin; Prospective Studies | 2021 |
Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Health Care Costs; Humans; Intensive Care Units; Length of Stay; Retrospective Studies | 2022 |
Personalized ß-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia: A retrospective analysis on pharmacokinetics and pharmacokinetic target attainment.
Topics: Aged; Aged, 80 and over; beta-Lactams; Body Mass Index; COVID-19 Drug Treatment; Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Retrospective Studies; SARS-CoV-2; Severity of Illness Index | 2021 |
Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Critical Care; Critical Illness; Cross Infection; Drug Monitoring; Female; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Renal Replacement Therapy; Retrospective Studies; Tertiary Care Centers; Young Adult | 2017 |
β-Lactams Dosing in Overweight Critically Ill Patients: Are We Driving in the Dark?
Topics: beta-Lactams; Critical Illness; Humans; Obesity; Overweight; Tazobactam | 2017 |
Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans | 2017 |
Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci study.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Critical Illness; Drug Therapy, Combination; Female; Hospital Mortality; Humans; Lactic Acid; Length of Stay; Logistic Models; Macrolides; Male; Middle Aged; Organ Dysfunction Scores; Pneumonia, Bacterial; Prognosis; Prospective Studies; Severity of Illness Index; Time Factors | 2018 |
Is a randomized trial of a short course of aminoglycoside added to β-lactam antibiotics for empirical treatment in critically ill patients with sepsis justified?
Topics: Aminoglycosides; beta-Lactams; Critical Illness; Drug Therapy, Combination; Humans; Intensive Care Units; Kidney; Observational Studies as Topic; Randomized Controlled Trials as Topic; Sepsis | 2018 |
Identifying "at-risk" patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Dose-Response Relationship, Drug; Humans; Infections; Intensive Care Units | 2017 |
Re: 'Is a randomized trial of a short course of aminoglycoside added to β-lactam antibiotics for empirical treatment in critically ill patients with sepsis justified?' Pharmacokinetic/pharmacodynamic considerations.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Sepsis | 2018 |
Beta-Lactam Therapeutic Drug Monitoring in the Critically Ill Children: Big Solution for Infections in Small People?
Topics: Anti-Bacterial Agents; beta-Lactams; Child; Critical Illness; Drug Monitoring; Humans; Intensive Care Units, Pediatric | 2018 |
Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Critical Illness; Drug Monitoring; Female; Humans; Logistic Models; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin; Prospective Studies; Treatment Outcome | 2018 |
Duration of Exposure to Antipseudomonal β-Lactam Antibiotics in the Critically Ill and Development of New Resistance.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cohort Studies; Critical Illness; Drug Resistance, Multiple, Bacterial; Female; Follow-Up Studies; Humans; Male; Middle Aged; Retrospective Studies; Sepsis; Shock, Septic; Tertiary Care Centers; Time Factors | 2019 |
Reply to Kollef et al.
Topics: Acute Kidney Injury; beta-Lactams; Critical Illness; Humans; Incidence; Vancomycin | 2020 |
Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Blood Proteins; Creatinine; Critical Illness; Drug Dosage Calculations; Drug Monitoring; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Protein Binding | 2013 |
Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Critical Illness; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; France; Humans; Intensive Care Units; Macrolides; Male; Middle Aged; Multivariate Analysis; Pneumonia, Bacterial; Prospective Studies; Risk Assessment; Survival Analysis; Time Factors | 2013 |
DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Blood Chemical Analysis; Critical Illness; Female; Humans; Intensive Care Units; International Cooperation; Male; Microbial Sensitivity Tests; Middle Aged; Models, Statistical; Prospective Studies; Treatment Outcome | 2014 |
Editorial commentary: Are blood concentrations enough for establishing pharmacokinetic/pharmacodynamic relationships?
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Critical Illness; Female; Humans; Male | 2014 |
Reply to Rhodes et al.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Critical Illness; Female; Humans; Male | 2014 |
Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Critical Illness; Female; Humans; Male | 2014 |
Antibiotic dosing in critically ill patients with septic shock and on continuous renal replacement therapy: can we resolve this problem with pharmacokinetic studies and dosing guidelines?
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Renal Replacement Therapy; Shock, Septic | 2014 |
Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Critical Illness; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Risk Factors | 2014 |
Elevated β-lactam concentrations associated with neurological deterioration in ICU septic patients.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Critical Care; Critical Illness; Disease Progression; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Nervous System Diseases; Pseudomonas aeruginosa; Retrospective Studies; Sepsis | 2015 |
Distribution of bla(OXA-23), ISAba , Aminoglycosides resistant genes among burned & ICU patients in Tehran and Sari, Iran.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Burns; Critical Illness; Cross Infection; DNA Transposable Elements; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Intensive Care Units; Iran; Microbial Sensitivity Tests; Polymerase Chain Reaction | 2014 |
Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Cohort Studies; Critical Illness; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Prospective Studies; Treatment Outcome; Young Adult | 2015 |
Augmented renal clearance and therapeutic monitoring of β-lactams.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Critical Illness; Female; Humans; Male | 2015 |
Even high-dose extended infusions may not yield desired concentrations of β-lactams: the value of therapeutic drug monitoring.
Topics: Adult; Amikacin; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Bacterial; Female; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Thienamycins | 2015 |
A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically Ill Patients.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Sepsis | 2015 |
Continuous infusion of β-lactam antibiotics for all critically ill patients?
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Infusions, Intravenous | 2016 |
The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for β-lactam administration and therapeutic drug monitoring among critically ill patients in France.
Topics: Adult; Aged; Anti-Bacterial Agents; Attitude of Health Personnel; beta-Lactams; Critical Illness; Cross-Sectional Studies; Drug Monitoring; Drug Utilization; Female; France; Humans; Male; Middle Aged; Professional Competence; Surveys and Questionnaires; Vancomycin | 2016 |
Should β-lactam antibiotics be administered by continuous infusion in critically ill patients? A survey of Australia and New Zealand intensive care unit doctors and pharmacists.
Topics: Anti-Bacterial Agents; Australia; beta-Lactams; Communicable Diseases; Critical Care; Critical Illness; Humans; Infusions, Intravenous; Intensive Care Units; New Zealand; Pharmacists; Physicians; Surveys and Questionnaires | 2016 |
Comparison of ß-lactam plus aminoglycoside versus ß-lactam plus fluoroquinolone empirical therapy in serious nosocomial infections due to Gram-negative bacilli.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Cohort Studies; Critical Illness; Cross Infection; Drug Therapy, Combination; Female; Fluoroquinolones; Gentamicins; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Proportional Hazards Models; Retrospective Studies; Tobramycin; Treatment Outcome | 2017 |
A microbiological method for determining serum levels of broad spectrum β-lactam antibiotics in critically ill patients.
Topics: Anti-Bacterial Agents; Bacteria; Bacteriological Techniques; beta-Lactams; Chromatography, Liquid; Critical Illness; Humans; Mass Spectrometry; Meropenem; Microbial Sensitivity Tests; Sweden; Thienamycins | 2016 |
Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Administration Schedule; Ertapenem; Female; Humans; Injections, Intravenous; Male; Middle Aged; Prospective Studies; Renal Dialysis | 2009 |
Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; beta-Lactams; Chromatography, High Pressure Liquid; Cohort Studies; Critical Illness; Ertapenem; Female; Humans; Male; Middle Aged; Plasma; Prospective Studies; Sepsis; Time Factors; Urine; Young Adult | 2009 |
Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Ertapenem; Humans; Monte Carlo Method; Plasma; Pneumonia, Bacterial | 2010 |
Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; beta-Lactams; Calibration; Critical Illness; Drug Dosage Calculations; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Empirical Research; Female; Humans; Male; Middle Aged; Models, Theoretical; Sepsis; Young Adult | 2010 |
Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential?
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Critical Illness; Drug Monitoring; Humans | 2010 |
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.
Topics: Adult; Aged; Anti-Bacterial Agents; APACHE; Bacterial Infections; beta-Lactams; Critical Illness; Drug Monitoring; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Treatment Outcome | 2010 |
β-lactam antibiotics in continuous infusion in critically ill patients.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Infusions, Intravenous; Sepsis | 2010 |
Pharmacokinetics of free ertapenem in critically ill septic patients: intermittent versus continuous infusion.
Topics: Aged; Anti-Bacterial Agents; Bacteria; beta-Lactams; Critical Illness; Ertapenem; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Sepsis | 2011 |
Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Creatinine; Critical Illness; Dose-Response Relationship, Drug; Female; Humans; Kidney; Kidney Function Tests; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Retrospective Studies; ROC Curve; Staphylococcal Infections; Treatment Outcome | 2012 |
Antibiotics in the critically ill: the bug, drug, host triad.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Female; Humans; Kidney; Male; Staphylococcal Infections | 2012 |
β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Critical Care; Critical Illness; Drug Monitoring; Female; Humans; Hypoalbuminemia; Kidney; Male | 2013 |
Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Chromatography, High Pressure Liquid; Creatinine; Critical Illness; Ertapenem; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Pneumonia, Ventilator-Associated; Prospective Studies; Treatment Outcome | 2007 |
Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; APACHE; beta-Lactams; Cohort Studies; Critical Illness; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Retrospective Studies | 2007 |